Table of Contents
International Journal of Proteomics
Volume 2011 (2011), Article ID 181890, 8 pages
http://dx.doi.org/10.1155/2011/181890
Review Article

Proteomics in Melanoma Biomarker Discovery: Great Potential, Many Obstacles

Department of Surgery, University of Michigan Health Systems, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA

Received 12 July 2011; Accepted 2 August 2011

Academic Editor: David E. Misek

Copyright © 2011 Michael S. Sabel et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Paik, S. Shak, G. Tang et al., “A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer,” The New England Journal of Medicine, vol. 351, no. 27, pp. 2817–2826, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. K. S. Albain, W. Barlow, S. Shak et al., “Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial,” The Lancet Oncology, vol. 11, no. 1, pp. 55–65, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Utikal, D. Schadendorf, and S. Ugurel, “Serologic and immunohistochemical prognostic biomarkers of cutaneous malignancies,” Archives of Dermatological Research, vol. 298, no. 10, pp. 469–477, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. H. Gogas, A. M. M. Eggermont, A. Hauschild et al., “Biomarkers in melanoma,” Annals of Oncology, vol. 20, pp. vi8–vi13, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Liu, P. Kirschmeier, J. Simon, C. Seidel-Dugan, and M. Puhlmann, “Prognostic and predictive molecular markers in cutaneous malignant melanoma: the first step toward personalized medicine,” Current Pharmacogenomics and Personalized Medicine, vol. 6, no. 4, pp. 272–294, 2008. View at Google Scholar · View at Scopus
  6. M. Deichmann, A. Benner, M. Bock et al., “S100-beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American joint committee on cancer stage IV melanoma,” Journal of Clinical Oncology, vol. 17, no. 6, pp. 1891–1896, 1999. View at Google Scholar · View at Scopus
  7. C. M. Balch, J. E. Gershenwald, S. Seng-Jaw et al., “Final version of 2009 AJCC melanoma staging and classification,” Journal of Clinical Oncology, vol. 27, no. 36, pp. 6199–6206, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. R. Dummer, R. Panizzon, P. H. Bloch, and G. Burg, “Updated Swill guidelines for the treatment and follow-up of cutaneous melanoma,” Dermatology, vol. 210, no. 1, pp. 39–44, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Garbe, D. Schadendorf, W. Stolz et al., “Short German guidelines: malignant melanoma,” Journal der Deutschen Dermatologischen Gesellschaft, vol. 6, no. 1, pp. S9–S15, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. R. Dummer, A. Hauschild, M. M. Guggenheim, L. Jost, and G. Pentheroudakis, “Melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up,” Annals of Oncology, vol. 21, no. 5, pp. v194–v197, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Ugurel, J. Utikal, and J. C. Becker, “Tumor biomarkers in melanoma,” Cancer Control, vol. 16, no. 3, pp. 219–224, 2009. View at Google Scholar · View at Scopus
  12. K. Bernard, E. Litman, J. L. Fitzpatrick et al., “Functional proteomic analysis of melanoma progression,” Cancer Research, vol. 63, no. 20, pp. 6716–6725, 2003. View at Google Scholar · View at Scopus
  13. F. Carta, P. P. Demuro, C. Zanini et al., “Analysis of candidate genes through a proteomics-based approach in primary cell lines from malignant melanomas and their metastases,” Melanoma Research, vol. 15, no. 4, pp. 235–244, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. P. Sinha, J. Poland, S. Kohl et al., “Study of the development of chemoresistance in melanoma cell lines using proteome analysis,” Electrophoresis, vol. 24, no. 14, pp. 2386–2404, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. M. A. Kern, H. Helmbach, M. Artuc, D. Karmann, K. Jurgovsky, and D. Schadendorf, “Human melanoma cell lines selected in vitro displaying various levels of drug resistance against cisplatin, fotemustine, vindesine or etoposide: modulation of proto-oncogene expression,” Anticancer Research, vol. 17, pp. 4359–4370, 1997. View at Google Scholar · View at Scopus
  16. W. M. Hardesty, M. C. Kelley, M. Deming, R. L. Low, and R. M. Caprioli, “Protein signatures for survival and recurrence in metastatic melanoma,” Journal of Proteomics, vol. 74, no. 7, pp. 1002–1014, 2011. View at Publisher · View at Google Scholar
  17. M. Stoeckli, P. Chaurand, D. E. Hallahan, and R. M. Caprioli, “Imaging mass spectrometry: a new technology for the analysis of protein expression in mammalian tissues,” Nature Medicine, vol. 7, no. 4, pp. 493–496, 2001. View at Publisher · View at Google Scholar · View at Scopus
  18. K. Rezaul, L. L. Wilson, and D. K. Han, “Direct tissue proteomics in human diseases: potential applications to melanoma research,” Expert Review of Proteomics, vol. 5, no. 3, pp. 405–412, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. B. L. Hood, M. M. Darfler, T. G. Guiel et al., “Proteomic analysis of formalin-fixed prostate cancer tissue,” Molecular and Cellular Proteomics, vol. 4, no. 11, pp. 1741–1753, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. S. R. Shi, C. Liu, B. M. Balgley et al., “Protein extraction from formalin-fixed paraffin-embedded tissue sections: quality evaluation by mass spectometry,” Journal of Histochemistry & Cytochemistry, vol. 54, no. 6, pp. 739–743, 2006. View at Publisher · View at Google Scholar
  21. X. Jiang, S. Feng, R. Tian, M. Ye, and H. Zou, “Development of efficient protein extraction methods for shotgun proteome analysis of formalin-fixed tissues,” Journal of Proteome Research, vol. 6, no. 3, pp. 1038–1047, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. D. E. Palmer-Toy, B. Krastins, D. A. Sarracino, J. B. Nadol, and S. N. Merchant, “Efficient method for the proteomic analysis of fixed and embedded tissues,” Journal of Proteome Research, vol. 4, no. 6, pp. 2404–2411, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. S. I. Hwang, J. Thumar, D. H. Lundgren et al., “Direct cancer tissue proteomics: a method to identify candidate cancer biomarkers from formalin-fixed paraffin-embedded archival tissues,” Oncogene, vol. 26, no. 1, pp. 65–76, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Takikawa, Y. Akiyama, T. Ashizawa et al., “Identification of melanoma-specific serological markers using proteomic analyses,” Proteomics—Clinical Applications, vol. 3, no. 5, pp. 552–562, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. H. J. Issaq, T. D. Veenstra, T. P. Conrads, and D. Felschow, “The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification,” Biochemical and Biophysical Research Communications, vol. 292, no. 3, pp. 587–592, 2002. View at Publisher · View at Google Scholar · View at Scopus
  26. T. W. Hutchens and T. T. Yip, “New desorption strategies for the mass spectrometric analysis of macromolecules,” Rapid Communications in Mass Spectrometry, vol. 7, pp. 576–580, 1993. View at Google Scholar
  27. J. Caron, A. Mange, B. Guillot, and J. Solassol, “Highly sensitive detection of melanoma based on serum proteomic profiling,” Journal of Cancer Research and Clinical Oncology, vol. 135, no. 9, pp. 1257–1264, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. L. L. Wilson, L. Tran, D. L. Morton, and D. S. B. Hoon, “Detection of differentially expressed proteins in early-stage melanoma patients using SELDI-TOF mass spectrometry,” Annals of the New York Academy of Sciences, vol. 1022, pp. 317–322, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Mian, S. Ugurel, E. Parkinson et al., “Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients,” Journal of Clinical Oncology, vol. 23, no. 22, pp. 5088–5093, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. P. Findeisen, M. Zapatka, T. Peccerella et al., “Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling,” Journal of Clinical Oncology, vol. 27, no. 13, pp. 2199–2208, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Greco, M. De Metri, F. Chiriaco, G. Leo, E. Brienza, and M. Maffia, “Serum proteomic profile of cutaneous malignant melanoma and relation to cancer progression: association to tumor derived alpha-N-acetylgalactosaminidase activity,” Cancer Letters, vol. 283, no. 2, pp. 222–229, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Neagu, C. Constantin, and C. Tanase, “Immune-related biomarkers for diagnosis/prognosis and therapy monitoring of cutaneous melanoma,” Expert Review of Molecular Diagnostics, vol. 10, pp. 897–919, 2010. View at Google Scholar
  33. A. Wankowicz-Kalinska, C. Le Poole, R. Van Den Wijngaard, W. J. Storkus, and P. K. Das, “Melanocyte-specific immune response in melanoma and vitiligo: two faces of the same coin?” Pigment Cell Research, vol. 16, no. 3, pp. 254–260, 2003. View at Publisher · View at Google Scholar · View at Scopus
  34. H. Uchi, R. Stan, M. J. Turk et al., “Unraveling the complex relationship between cancer immunity and autoimmunity: lessons from melanoma and vitiligo,” Advances in Immunology, vol. 90, pp. 215–241, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. T. Ramirez-Montagut, M. J. Turk, J. D. Wolchok, J. A. Guevara-Patino, and A. N. Houghton, “Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity,” Oncogene, vol. 22, no. 20, pp. 3180–3187, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Suzuki, A. Iizuka, M. Komiyama et al., “Identification of melanoma antigens using a serological proteome approach (SERPA),” Cancer Genomics and Proteomics, vol. 7, no. 1, pp. 17–23, 2010. View at Google Scholar · View at Scopus
  37. Y. Liu, J. He, X. Xie et al., “Serum autoantibody profiling using a natural glycoprotein microarray for the prognosis of early melanoma,” Journal of Proteome Research, vol. 9, no. 11, pp. 6044–6051, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. E. P. Diamandis, “Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems,” Journal of the National Cancer Institute, vol. 96, no. 5, pp. 353–356, 2004. View at Google Scholar · View at Scopus
  39. E. P. Diamandis, “Proteomic patterns in biological fluids: do they represent the future of cancer diagnostics?” Clinical Chemistry, vol. 49, no. 8, pp. 1272–1275, 2003. View at Publisher · View at Google Scholar · View at Scopus
  40. P. R. Srinivas, M. Verma, Y. Zhao, and S. Srivastava, “Proteomics for cancer biomarker discovery,” Clinical Chemistry, vol. 48, no. 8, pp. 1160–1169, 2002. View at Google Scholar · View at Scopus
  41. R. J. Simpson and D. S. Dorow, “Cancer proteomics: from signaling networks to tumor markers,” Trends in Biotechnology, vol. 19, supplement 10, pp. S40–S48, 2001. View at Google Scholar · View at Scopus
  42. B. Franzen, T. Hirano, K. Okuzawa et al., “Sample preparation of human tumors prior to two-dimensional electrophoresis of proteins,” Electrophoresis, vol. 16, no. 7, pp. 1087–1089, 1995. View at Google Scholar · View at Scopus
  43. R. E. Banks, M. J. Dunn, M. A. Forbes et al., “The potential use of laser capture microdissection to selectively obtain distinct populations of cells for proteomic analysis—preliminary findings,” Electrophoresis, vol. 18, pp. 622–624, 1999. View at Google Scholar · View at Scopus
  44. H. T. Tan, J. Low, S. G. Lim, and M. C. M. Chung, “Serum autoantibodies as biomarkers for early cancer detection,” FEBS Journal, vol. 276, no. 23, pp. 6880–6904, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. M. S. Pepe, R. Etzioni, Z. Feng et al., “Phases of biomarker development for early detection of cancer,” Journal of the National Cancer Institute, vol. 93, no. 14, pp. 1054–1056, 2001. View at Google Scholar · View at Scopus
  46. V. Paulitschke, R. Kunstfeld, T. Mohr et al., “Entering a new era of rational biomarker discovery for early detection of melanoma metastases: secretome analysis of associated stroma cells,” Journal of Proteome Research, vol. 8, no. 5, pp. 2501–2510, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. B. L. Hood, J. Grahovac, M. S. Flint et al., “Proteomic analysis of laser microdissected melanoma cells from skin organ cultures,” Journal of Proteome Research, vol. 9, no. 7, pp. 3656–3663, 2010. View at Publisher · View at Google Scholar · View at Scopus